To further its mission, CBR collaborates with several like-minded organisations, particularly in the realm of neurodegeneration research. These exciting partnerships are expected to synergise with and provide impetus to CBR’s research efforts.
SKAN, a public charitable trust set up by the Soota and Karedan families, aims to promote research and development in medical science, with a focus on the treatment of geriatric and neurological diseases. CBR’s partnership with SKAN will focus on research on Parkinson’s disease, bipolar disorders, strokes, and common linkages between different neurological disorders. As SKAN’s strategic partner for neurological research, CBR is building a consortium of partners to handle the first project on Parkinson’s disease.
The ADDI, a US-based charitable medical research organization, is dedicated to transforming Alzheimer’s disease (AD) research, accelerating progress towards new treatments and cures for AD and related dementias. CBR partners with the ADDI to make data on longitudinal studies of aging available for researchers worldwide to promote collaboration.
“The COVID-19 crisis has demonstrated the need for global collaboration. I am optimistic that this partnership with ADDI will not only drive more dementia research across the globe but will promote global collaboration to end Alzheimer’s disease and related dementias.” – Dr Kris Gopalakrishnan, Founder Trustee, Pratiksha Trust.
CBR secured funding from Fidelity Bermuda Foundation for a research project titled ‘The BANGLE project: Bangalore Edinburgh Collaboration for Brain Health and Dementia Prevention’ under the direction of Professor Graciela Muniz Terrera, Chair of Ageing, Health and Methods in the Edinburgh Dementia Prevention research group, University of Edinburgh, UK.